Clinical trials in the development of new medical device products are in many ways analogous to clinical trials in the development of new drug or biologic products. However, the differences are important and not always intuitive to a statistician with only experience supporting development of drug and biologic products. In this paper we discuss some of the interesting differences with focus on the statistical innovation that is coming out of the medical device area. We discuss examples of the differences in clinical trial design and effects of these differences on clinical development programs.
CampbellG. Statistics in the world of medical devices: the contrast with pharmaceuticals. J Biopharm Stat. 2007;18:4–19.
3.
14155:2011(en) Clinical Investigation of Medical Devices for Human Subjects—Good Clinical Practice. Geneva, Switzerland: International Organization for Standardization; 2011.
LiHYueLQ. Statistical and regulatory issues in nonrandomized medical device clinical studies. J Biopharm Stat. 2007;18:20–30.
6.
The Least Burdensome Provisions of the FDA Modernization Act of 1997: Concept and Principles; Final Guidance for FDA and Industry. Rockville, MD: Food and Drug Administration; 2002.
7.
Draft Guidance for Industry, Clinical Investigators, and Food and Drug Administration Staff—Design Considerations for Pivotal Clinical Investigations for Medical Devices. Rockville, MD: Food and Drug Administration, 2011.
8.
11979–7:2006(en) Clinical Investigation of Medical Devices for Human Subjects—Good Clinical Practice. Geneva, Switzerland: International Organization for Standardization; 2011.
9.
RothmannMDWiensBLChanISF. Design and Analysis of Non-Inferiority Trials. Boca Raton, FL: CRC Press; 2012.
10.
O’MalleyAJNormandSTKuntzRE. Application of multivariate mixed outcomes to medical device trials: coronary artery stenting. Stat Med. 2003;22:313–336.
11.
Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. Rockville, MD: Food and Drug Administration; 2012.
12.
SimonNSimonR. Adaptive enrichment designs for clinical trials. Biostat. 2013;14:613–625.
13.
RosenblumMVan Der LaanMJ. Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika. 2011;98:845–860.
14.
Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials. Rockville, MD: Food and Drug Administration; 2010.
PennelloGThompsonL. Experience with reviewing Bayesian medical device trials. J Biopharm Stat. 2008;18:81–115.
17.
HobbsBPCarlinBP. Practical Bayesian design and analysis for the drug and device clinical trials. J Biopharm Stat. 2007;18:54–80.
18.
HobbsBPSargentDJCarlinBP. Commensurate priors for incorporating historical information in clinical trials using general and generalized linear models. Bayesian Analysis. 2012;7:639–674.
19.
MurrayTAHobbsBPLystigTC, Carlin BP. Composite Kaplan-Meier and Semiparametric Commensurate Bayesian Models for post-Market Medical Device Surveillance With Historical Survival Information (Research Report 2013-004). Minneapolis, MN: Division of Biostatistics, University of Minnesota; 2013.
